Role of COE networks in curative cellular oncology therapies

Eric NormanFoCUS, Research Briefs

COE networks currently play an important role in the delivery of care for specialized service lines, including but not limited to solid organ transplantation (SOT), hematopoietic cell transplantation (HCT) and … Read More

Designing financial solutions to ensure affordable access to cures

Eric NormanFoCUS, Whitepapers

The reimbursement of emerging durable/potentially curative cell and gene therapies is likely to be a challenge for the US healthcare market. Considering the pricing of cell- and gene-based therapies approved … Read More

Stop-Loss Insurance or Reinsurance for Multiyear Contracts

Eric NormanFoCUS, Research Briefs

In previous Research Briefs, we have discussed challenges faced by payers when contemplating using multiyear performance-based contracts. In this brief, we extend the discussion to include additional difficulties that may … Read More

Impact of Patient Mobility on Annuity/Performance-Based Contracting

Eric NormanFoCUS, Research Briefs

Spreading payments over time for durable or curative therapies can provide a better alignment between benefits and costs, but creates challenges when patients switch insurance coverage during the contract term. … Read More

Orphan Reinsurer Benefit Managers (ORBMs)

Eric NormanFoCUS, Research Briefs

An Orphan Reinsurer Benefit Manager (ORBM) could address the financial challenges (payment timing, therapeutic performance risk, actuarial risk), created by durable/potentially curable gene and cell therapies especially for smaller insurers … Read More